Definium Therapeutics, Inc. - DFTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 1.8% | 2,410,000 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 1.8% | 2,410,000 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 1.8% | 2,410,000 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Michael Kramarz | 1.8% | 2,410,000 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | DRIEHAUS CAPITAL MANAGEMENT LLC | 5.36% | 6,845,276 | View |
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 3.01% | 3,000,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 3.01% | 3,000,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | David Kroin | 3.01% | 3,000,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.